Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 2XP HEPTAVAX™-II SC
2XP HEPTAVAX-II · 1 trial · 1 indication
Blood samples were collected for anti-hepatitis B antibody assays. Seroprotection was defined as ≥10 mIU/mL anti-hepatitis B antibody.
Participants were evaluated for injection-site adverse events using MedDRA version 15.1
Participants were evaluated for pyrexia adverse events using MedDRA version 15.1. Pyrexia (fever) was defined as an oral temperature ≥37.8°C ( ≥100.0°F).
| Arm | Type | Description |
|---|---|---|
| V232-2XP SC | EXPERIMENTAL | 2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6 |
| V232-1XP SC | ACTIVE_COMPARATOR | 1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6 |
| V232-2XP IM | EXPERIMENTAL | 2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6 |
| Name | Type | Description |
|---|---|---|
| 2XP HEPTAVAX™-II SC | BIOLOGICAL | - |
| 1XP HEPTAVAX™-II SC | BIOLOGICAL | - |
| 2XP HEPTAVAX™-II IM | BIOLOGICAL | - |
Inclusion Criteria: To receive the first study vaccination, Participants should meet all inclusion criteria. * Participants provide written informed consent for the trial. The Participant may also provide consent for Future Biomedical Research. However, the Participant may participate in the main ...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
2XP HEPTAVAX-II is a vaccine being developed for the prevention of hepatitis B. It is intended to induce protective immunity against hepatitis B virus infection. The vaccine is in Phase 3 clinical development and has been studied in Japanese young adults.
2XP HEPTAVAX-II is developed by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is the sponsor of the clinical trial evaluating this vaccine candidate.
2XP HEPTAVAX-II is in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The vaccine remains investigational and has not been approved by the FDA.
2XP HEPTAVAX-II has been evaluated in a completed Phase 3 trial, NCT01463683, titled Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062). The trial enrolled 722 participants, was randomized, double-blind, and used an active control.
Yes, 2XP HEPTAVAX-II SC is an alternative name for 2XP HEPTAVAX-II. The SC designation refers to the subcutaneous route of administration. Both names refer to the same hepatitis B vaccine candidate developed by Merck.